Encouraging response for monotherapy dose-escalation study
Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours.
These results were presented after market close at an AACR Special Conference in Cancer Research.
“Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive cancers,” said Dr David Hallett, Chief Scientific Officer of Recursion. “By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half-life to manage side effects, and target engagement covering the IC80 level.”
Trial details
ELUCIDATE is an ongoing Phase I/II study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of REC-617 in patients with advanced solid tumours. As of 15 November 2024, data cut-off, preliminary findings include 18 patients with advanced solid tumours who were response evaluable in the monotherapy dose-escalation phase. Doses ranged from 2mg to 20mg once daily (QD) and 1mg twice daily (BID).
REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached.
While efficacy was not an endpoint in this Phase I study, or anticipated in monotherapy, a confirmed durable partial response (PR) by RECIST on REC-617 monotherapy was achieved in a patient with metastatic, platinum-resistant ovarian cancer. The response is on-going after more than six months of treatment. This patient had progressed following four lines of prior therapy in the advanced setting. In addition, four patients achieved a best response of stable disease (SD) across multiple dose levels for up to six months of treatment.
“These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favourable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population,” said Dr Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year.”
In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate for ELUCIDATE in H1, 2025. The company expects to present additional ELUCIDATE as well as preclinical REC-617 data at future medical meetings.
Summary of dose escalation results
Study design & demographics
- Phase I monotherapy dose escalation in advanced solid tumours
- Data cut-off as of 15 November 2024 – 19 patients enrolled (18 response evaluable)
- Heavily pre-treated population (median of four prior lines of therapy in the advanced setting)
- Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhoea
PK/PD summary
- REC-617 exceeds CDK7 IC80 with rapid absorption (Tmax 0.5–2 hours) with a half-life of 5-6 hours
- Early POLR2A three to four times modulation suggests ~80–90% target engagement
- Quick, time-limited target engagement with POLR2A normalisation in 24 hours
- Twice-daily (BID) dosing under investigation
Safety profile/AE summary
- Adverse events (AEs) were predominantly low grade, on-target, and reversible upon treatment cessation
- Early data indicates a favourable safety profile – maximum tolerated dose (MTD) not reached
- No treatment discontinuations due to AEs
- Three treatment related serious adverse events (SAE)s reported in two out of 19 patients
- Events resolved and treatment continued after dose reduction
- Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhoea
Confirmed partial response and stable disease summary
- One confirmed partial response (PR) by RECIST 1.1 (decrease of more than 30% in the sum of the longest diameters of target lesions + no new lesions + no progression of non target lesions)
- Partial response (-34%) achieved with reduction of two lymph nodes (para-aortic and mesenteric) at Week 16 with normalisation of LDH
- Reduction of tumour marker CA125 from 1249 to 694 kU/L (-44%)
- Reduction of tumour marker TK1 from 174 to 56 DuA (-68%)
- Response ongoing after more than 6 months of treatment
- Patient continues study therapy without need for antiemetics
- Four additional patients achieved durable (up to six months of treatment) response of stable disease (SD) as best response across multiple dose levels
- All four patients progressed prior to entering the study
- Three CRC patients (6L-7L) and one NSCLC patient (4L)
- One patient on 2mg QD and three patients on 10mg QD
Megan Thomas, Multimedia Editor, DDW
